Medical Oncologist
HER2-positive breast cancer
Adjuvant Trastuzumab: — Why Exactly 12 Months?
You have been told trastuzumab will run for 12 months after surgery. This page explains why that number is fixed, what counts toward it, and why trastuzumab in advanced breast cancer follows completely different rules.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- 12 months is evidence-based — The duration comes from clinical trials. Giving it for longer did not improve outcomes.
- Neoadjuvant doses count — If you had trastuzumab before surgery, those infusions are included in the total 12-month course.
- Adjuvant and metastatic are different — In advanced breast cancer, trastuzumab continues indefinitely. The 12-month rule applies only to early-stage treatment after surgery.
- It is given as day care — Each infusion takes a few hours. You go home the same day.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
In the adjuvant setting — after surgery for early-stage HER2-positive breast cancer — trastuzumab runs for 12 months in total. This includes any doses given before surgery. NCCN and ASCO guidelines treat 12 months as the standard; giving it for longer has not been shown to improve outcomes.
What do these terms actually mean?
- Adjuvant therapy
- Treatment given after surgery to lower the chance of the cancer returning. The surgery removes the tumour; adjuvant therapy targets any cancer cells that may remain elsewhere.
- Neoadjuvant therapy
- Treatment given before surgery. It can shrink the tumour ahead of the operation. Any trastuzumab given in this phase counts toward your total 12-month course — the clock starts at your first infusion, not at surgery.
- HER2-positive
- A type of breast cancer in which tumour cells carry too many copies of the HER2 protein. Trastuzumab is designed to block that protein. It is only used when HER2 testing confirms the cancer is positive.
- Early-stage breast cancer
- Cancer that has not spread to distant organs. It may involve nearby lymph nodes but has not reached the lungs, liver, brain or bones. The 12-month adjuvant rule applies in this setting.
- Metastatic breast cancer
- Cancer that has spread to distant organs — Stage IV. Trastuzumab in this setting is not limited to 12 months. The goals, the combinations used, and the duration are all different from early-stage treatment.
Why does the adjuvant course stop at 12 months and not earlier or later?
The 12-month figure comes from clinical evidence, not from an arbitrary rule. Large trials including the HERA trial, referenced in NCCN and ASCO guidelines, compared 12 months of trastuzumab against 24 months in early-stage HER2-positive breast cancer. Two years produced no improvement over one year.
Shorter courses have also been studied. In some analyses they performed less well, which is why most guidelines have settled on 12 months as the evidence-based standard rather than shortening it.
Trastuzumab also carries a risk of affecting heart function, and your team monitors this throughout the course. This is one reason the duration is not extended indefinitely — the risk-to-benefit balance is most clearly supported at the 12-month endpoint.
The clock starts at your first infusion, whether that was before or after surgery. If you had several months of neoadjuvant trastuzumab, your adjuvant phase completes the remaining time to reach the full course.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What should you keep track of during your 12 months of trastuzumab?
- Know your start dateIt is the date of your very first trastuzumab infusion — before surgery if you had neoadjuvant treatment, or after surgery if adjuvant-only.
- Record each infusion dateKeep your own log. If there is ever a delay or a discrepancy, your record is the clearest reference.
- Attend every heart scanYour team will schedule echocardiograms or MUGA scans at intervals during treatment. These check that your heart is tolerating the drug. Missing them can delay your next infusion.
- Report breathlessness or leg swelling the same dayNew shortness of breath, swelling in the legs, or a rapid heartbeat are cardiac warning signs. Do not wait for your next scheduled visit — call your team the same day.
- Tell your team if pregnancy is possibleTrastuzumab is not safe in pregnancy. If this applies to you, your oncologist needs to know before treatment starts.
- Ask for your planned end dateYou should know exactly when your final infusion is scheduled. A pause for monitoring may shift that date, and your team will recalculate the endpoint each time.
If someone you know takes trastuzumab for years, why is your course only 12 months?
They almost certainly have metastatic or advanced HER2-positive breast cancer — Stage IV, where the cancer has spread to other organs. That is a fundamentally different situation from early-stage treatment after surgery, even though the drug is the same.
In the metastatic setting, trastuzumab is not given for a fixed period. It continues for as long as the cancer is responding and side effects remain manageable. For some people that means several years.
The goals are different in each setting. In the adjuvant setting, the aim is to reduce the chance of the cancer returning in someone whose surgery removed the tumour. In the metastatic setting, the aim is to control a disease already present in distant organs — stopping would allow it to progress.
If you are being treated for early-stage disease, your 12-month course is correct for your situation. If your circumstances change later, your oncologist will explain at that point how the approach would differ.
Explore 75 more Breast Cancer Targeted Medicines topics
Drug Deep Dive: Trastuzumab (Herceptin)
- Adjuvant Trastuzumab: Why Exactly 12 Months After Surgery?
- Diet and Nutrition While on Trastuzumab
- Drug, Food and Supplement Interactions With Trastuzumab
- Fatigue, Chills and Flu-Like Symptoms After a Trastuzumab Infusion
- Fertility, Pregnancy and Contraception on Trastuzumab
- Heart Function and Trastuzumab: Understanding Your ECHO Reports
- Herceptin vs Biosimilar Trastuzumab: Are They Really the Same?
- How Does Trastuzumab Work? The Anti-HER2 Monoclonal Antibody Explained
- How Long Does Trastuzumab Take to Work?
- How Long Will You Stay on Trastuzumab?
- Subcutaneous Trastuzumab vs IV Infusion: Which Suits You Better?
- Tests and Monitoring While You Are on Trastuzumab
- Trastuzumab (Herceptin and biosimilars): The Complete Patient Guide
- Trastuzumab Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Infusion Reactions: What Happens and How They're Managed
- Trastuzumab Myths: 'It's Chemotherapy' and Other Misunderstandings
- Trastuzumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Side Effects: The Complete List and Timeline
- Trastuzumab Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab With Pertuzumab, Chemotherapy and Hormone Therapy
- Trastuzumab in Elderly Patients and Those With Other Illnesses
- When Trastuzumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Trastuzumab? HER2-Positive Breast and Gastric Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab?
- Work, Travel and Daily Life on Trastuzumab
Drug Deep Dive: Palbociclib (Ibrance)
- Diet and Nutrition While on Palbociclib
- Drug, Food and Supplement Interactions With Palbociclib
- Fatigue on Palbociclib: Why It Happens and What Genuinely Helps
- Fertility, Pregnancy and Contraception on Palbociclib
- How Does Palbociclib Work? The CDK4/6 Inhibitor Explained
- How Long Does Palbociclib Take to Work?
- How Long Will You Stay on Palbociclib?
- Low White Cell Count on Palbociclib: Expected, and Rarely Dangerous
- Mouth Sores and Infection Risk on Palbociclib
- Palbociclib (Ibrance, Palbace): The Complete Patient Guide
- Palbociclib Myths: Low Counts, Hair Loss and Stopping Early
- Palbociclib Price in India: Brand, Generic and Monthly Cost
- Palbociclib Side Effects: The Complete List and Timeline
- Palbociclib Success Rate and Survival: An Honest Look at the Numbers
- Palbociclib With Letrozole or Fulvestrant: Understanding Your Combination
- Palbociclib in Early Breast Cancer: Why It Is Not Given After Surgery
- Palbociclib in Elderly Patients and Those With Other Illnesses
- Palbociclib vs Ribociclib vs Abemaciclib: Which CDK4/6 Inhibitor?
- Taking Palbociclib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Palbociclib
- The 21-Days-On, 7-Days-Off Palbociclib Cycle Explained
- When Palbociclib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Palbociclib? Hormone-Receptor-Positive, HER2-Negative Breast Cancer
- Will Insurance or a Government Scheme Pay for Palbociclib?
- Work, Travel and Daily Life on Palbociclib
Drug Deep Dive: Trastuzumab Deruxtecan (Enhertu)
- Diet and Nutrition While on Trastuzumab Deruxtecan
- Drug, Food and Supplement Interactions With Trastuzumab Deruxtecan
- Enhertu Myths: 'It's Just Stronger Herceptin' and Cost Misconceptions
- Enhertu in Breast, Gastric and Lung Cancer: One Drug, Three Diseases
- Fertility, Pregnancy and Contraception on Trastuzumab Deruxtecan
- HER2-Low Breast Cancer: How Enhertu Created an Entirely New Patient Group
- How Does Trastuzumab Deruxtecan Work? The HER2-Directed Antibody-Drug Conjugate Explained
- How Long Does Trastuzumab Deruxtecan Take to Work?
- How Long Will You Stay on Trastuzumab Deruxtecan?
- Interstitial Lung Disease on Enhertu: The Side Effect That Needs Immediate Action
- Low Blood Counts, Hair Loss and Heart Monitoring on Enhertu
- Nausea and Vomiting on Trastuzumab Deruxtecan: Managing a High-Risk ADC
- Tests and Monitoring While You Are on Trastuzumab Deruxtecan
- Trastuzumab Deruxtecan (Enhertu): The Complete Patient Guide
- Trastuzumab Deruxtecan Infusion Day: Premedication, Duration and What to Expect
- Trastuzumab Deruxtecan Price in India: Innovator, Biosimilar and Cost Per Cycle
- Trastuzumab Deruxtecan Side Effects: The Complete List and Timeline
- Trastuzumab Deruxtecan Success Rate and Survival: An Honest Look at the Numbers
- Trastuzumab Deruxtecan in Elderly Patients and Those With Other Illnesses
- Trastuzumab Deruxtecan vs T-DM1 and Trastuzumab: How ADCs Differ
- When Trastuzumab Deruxtecan Stops Working: Resistance and What Comes Next
- Where Trastuzumab Deruxtecan Fits Alongside Chemotherapy and Hormone Therapy
- Who Is Eligible for Trastuzumab Deruxtecan? HER2-Positive and HER2-Low Breast, Gastric and Lung Cancer
- Will Insurance or a Government Scheme Pay for Trastuzumab Deruxtecan?
- Work, Travel and Daily Life on Trastuzumab Deruxtecan
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does the trastuzumab I had before surgery count toward the 12 months?
Yes. The total 12-month course includes both the neoadjuvant phase before surgery and the adjuvant phase after. If you had several months of neoadjuvant trastuzumab, your adjuvant phase completes the remaining time. Your oncologist calculates this from your first infusion date, not from your surgery date.
What happens if I miss an infusion or have to pause treatment?
A gap — for illness, a procedure, or a heart scan result that needs time to recover — does not restart the course from zero. Your team records the gap and adjusts your planned end date accordingly. What matters is completing the full course, not completing it within a rigid calendar window. Tell your team about any delay as soon as you know, so they can reschedule the remaining infusions.
Why not give trastuzumab for longer if it seems to be working?
The clinical trials that established 12 months also tested 24 months and found no additional benefit — this is reflected in both NCCN and ASCO guidelines. More treatment is not always more effective. Trastuzumab also carries a monitored risk to heart function, and the evidence supporting the 12-month endpoint is the clearest basis for the risk-to-benefit decision your oncologist makes.
Will I need trastuzumab again if the cancer comes back?
If the cancer returns as metastatic disease, trastuzumab may well be part of the new treatment plan — but in that setting it would not be limited to 12 months. It is often combined with other agents, and the exact approach depends on where the cancer has spread, how much time has passed, and your current health. Your oncologist would assess this fully at that point.
What monitoring happens during the 12-month course?
Heart function is the main focus. Your team will schedule echocardiograms — an ultrasound of the heart — or MUGA scans at regular intervals. If your heart function drops below a certain level, treatment may be paused until it recovers. Routine blood tests are also done at each visit. The frequency of heart scans varies depending on your individual results and your centre's protocol.
What happens after the 12 months end?
Trastuzumab stops, and you move into a follow-up phase. This typically involves regular clinic appointments and imaging for several years. If your cancer was also hormone receptor-positive, you may continue a separate hormonal therapy alongside or after the trastuzumab course. Ask your oncologist at your next visit what your specific follow-up schedule looks like and what signs would prompt an earlier review.